Article Versions Notes

Suemura S, Kodama T, Myojin Y, Yamada R, Shigekawa M, Hikita H, Sakamori R, Tatsumi T, Takehara T. CRISPR Loss-of-Function Screen Identifies the Hippo Signaling Pathway as the Mediator of Regorafenib Efficacy in Hepatocellular Carcinoma. Cancers. 2019; 11(9):1362. https://doi.org/10.3390/cancers11091362

Suemura, Shigeki, Takahiro Kodama, Yuta Myojin, Ryoko Yamada, Minoru Shigekawa, Hayato Hikita, Ryotaro Sakamori, Tomohide Tatsumi, and Tetsuo Takehara. 2019. "CRISPR Loss-of-Function Screen Identifies the Hippo Signaling Pathway as the Mediator of Regorafenib Efficacy in Hepatocellular Carcinoma" Cancers 11, no. 9: 1362. https://doi.org/10.3390/cancers11091362

Suemura, S., Kodama, T., Myojin, Y., Yamada, R., Shigekawa, M., Hikita, H., Sakamori, R., Tatsumi, T., & Takehara, T. (2019). CRISPR Loss-of-Function Screen Identifies the Hippo Signaling Pathway as the Mediator of Regorafenib Efficacy in Hepatocellular Carcinoma. Cancers, 11(9), 1362. https://doi.org/10.3390/cancers11091362